Pruritic rash and nocturnal itching.

J Fam Pract

Dermatology Underserved Fellowship in Family Medicine (Dr. Zha) and Department of Family Medicine and Department of Dermatology and Cutaneous Surgery (Dr. Usatine), University of Texas Health, San Antonio.

Published: October 2023

UV light illuminated the patient's diagnosis.

Download full-text PDF

Source
http://dx.doi.org/10.12788/jfp.0675DOI Listing

Publication Analysis

Top Keywords

pruritic rash
4
rash nocturnal
4
nocturnal itching
4
itching light
4
light illuminated
4
illuminated patient's
4
patient's diagnosis
4
pruritic
1
nocturnal
1
itching
1

Similar Publications

Dermatologic Adverse Events Following Afatinib in a Woman with Non-Small-Cell Lung Cancer: A Case Report.

Clin Cosmet Investig Dermatol

January 2025

Department of Dermatology and Venereology, Faculty of Medicine, Universitas Padjadjaran-Dr Hasan Sadikin Hospital, Bandung, West Java, Indonesia.

Epidermal growth factor receptor inhibitors (EGFRI) are biological factors used in several types of cancer, including non-small-cell lung cancers (NSCLC). One of the EGFR inhibitors that has been approved for NSCLC is afatinib. Dermatologic adverse events are the most commonly reported and may impair the patient's compliance to the therapy as it causes aesthetic discomfort and significantly impact the patient's quality of life.

View Article and Find Full Text PDF

Background: The efficacy and safety of dupilumab in patients with refractory prurigo nodularis (PN) is well established in clinical trials, but there is a lack of multicenter data regarding its effectiveness and safety in real-world settings.

Methods: Patients with moderate-to-severe PN who initiated dupilumab treatment between July 2023 and January 2024, with a follow-up period of at least 16 weeks at 10 hospitals in China were included. We used peak pruritus numeric rating scale (PP-NRS), investigator global assessment (IGA) for PN, and dermatology life quality index for adults or children (DLQI/CDLQI) to assess disease control status and quality of life impairment, and monitored adverse events to assess the safety.

View Article and Find Full Text PDF

Considering the increasing use of immune checkpoint inhibitors in cancer treatment, our aim is to report a rare cutaneous immune-related adverse event induced by PD-1 inhibitor pembrolizumab and provide a brief overview of pembrolizumab-induced subacute cutaneous lupus erythematosus (SCLE) cases in the literature. We report a 67-year-old woman with oropharyngeal squamous cell carcinoma who developed SCLE during treatment with pembrolizumab. After 18 weeks (sixth cycle) of pembrolizumab immunotherapy, a widespread pruritic erythematous rash evaluated as grade 3 immune-related adverse event appeared primarily on the patient's limbs.

View Article and Find Full Text PDF

An 89-year-old male with a medical history of non-ischemic cardiomyopathy was initially admitted with acute hypoxic respiratory failure attributed to heart failure exacerbation. Aside from progressive dyspnea, a non-pruritic, non-painful rash and constitutional symptoms were reported. Initial work-up was remarkable for normocytic anemia, lymphopenia, mild hypercalcemia, and elevated inflammatory markers.

View Article and Find Full Text PDF

Prurigo Pigmentosa is a rare inflammatory skin disease of unknown origin, characterized by pruritic, erythematous papules on the chest, back, neck, and anterior abdomen. The eruption resolves with reticular hyperpigmentation that cosmetically affects the patient's quality of life. Previous reports highlighted the role of the Ketogenic diet in triggering the disease in young female patients, however, no study reported the occurrence of Prurigo Pigmentosa in siblings of one family, unrelated to a ketogenic diet.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!